The Wound Care Centre of the Hyperbaric Centre of Ravenna is testing a latest-generation product to treat wounds that do not heal easily: Klox LumiHeal.
KLOX Therapy is a treatment that employs Photobiomodulation, that is to say the visible light capacity to trigger non-thermal and non-cytotoxic biological reactions.
The therapy consists of the application of a chromophores gel (chromophores are a group of atoms that can impart a colour to a specific substance) and urea peroxide. Once applied on the wound and on the perilesional skin, the gel is submitted to a non-coherent blue light emitted from a LED lamp 5 cm proximal from the wound.
The exposure lasts 5 minutes; after that the gel is eliminated and you can proceed with the most suitable treatment and bandage.
Contrary to what you can think, the chromophores are not the ones acting directly to support the healing processes; their sole purpose is to modulate the light, thus allowing it to reach different wavelengths.
- The blue light reaches the most superficial layers of the wound (from 450 to 500nm) and it can control the bacterial colonization and reduce the inflammation; this is the reason why the best results have been achieved with rheumatic ulcers, that is to say with “inflammatory origin”.
- Then there is the green light, which deeply penetrates the skin (500-570 nm) and stimulates the fibroblasts proliferation and therefore the reepithelization.
- The yellow/orange light that assists the growth of the blood vessels and the wound contraction is the one that reaches the deepest layers of the derma (570-610 nm).
It is precisely the light that acts directly on the wound; the chromophores are just the 50%.
This is how the chemical-physical process that triggers the reaction works: when the light hits the chromophores molecules, the electrons go from a state of rest to a state of excitement, to immediately go back to a ground state. Therefore, you have a light emission of micropulse photons, which transforms the blue light into different wavelengths associated to the colours explained before. This phenomenon is only possible through the presence of an oxidant, specifically the urea peroxide contained in the gel carrier, which has an active role in the debridement process. Indeed, in this case there is the biofilm breaking.
The producer suggests applying the product at intervals of at least 48 hours on acute or chronic venous lesions. Our clinical experience revealed that the ulcers that give better response to this treatment are the rheumatic ones.
We have been able to establish as well that patent benefits can be reached also by applying the product during the treatment, thus not complying with the 48 hours standard.
Product testing is monitored by the directorate of our Centre and supervised by the Medical Director, Dr. Pasquale Longobardi and by the Head of Nursing of the Wound Care Centre Klarida Hoxha.
Sofia Fioravanti, nurse of the Wound Care Centre of the Hyperbaric Centre of Ravenna